The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells.

Al-Keilani, Maha S; Alzoubi, Karem H; Jaradat, Saied A.

Afiliação

Al-Keilani MS; Department of Clinical Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan, mskeilani@just.edu.jo.
Alzoubi KH; Department of Clinical Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan, mskeilani@just.edu.jo.
Jaradat SA; Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, Jordan.

Clin Pharmacol ; 10: 135-140, 2018.

Article em En | MEDLINE | ID: mdl-30349406